Control de la tuberculosis multirresistente a fármacos: un objetivo posible

Organización de las Naciones Unidas. Objetivos de desarrollo sostenible. Ginebra: Organización de las Naciones Unidas; 2015. p. 1-5. http://www.un.org/
sustainabledevelopment/es/objetivos-de-desarrollo-sostenible/
2. O’Neill J. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. 2016. Fecha de consulta: 10 de agosto de 2019. Disponible en: https://www.mendeley.com/catalogue/antimicrobial-resistance-tackling-crisis-health-wealth-nations/
3. Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al. Building a tuberculosis-free world: The Lancet Commission on Tuberculosis. Lancet. 2019;393:1331-84. https://doi.org/10.1016/S0140-6736(19)30024-8
4. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. Geneva. 2013. Fecha de consulta: 10 de agosto de 2019. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/112472/9789241506335_eng.pdf;jsessionid=F268607C867
5. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement. Geneva: 2008. Fecha de consulta: 13 de agosto de 2019. Disponible en: https://www.who.int/tb/features_archive/policy_statement.pdf
6. Vesga JF, Hallett TB, Reid MJA, Sachdeva KS, Rao R, Khaparde S, et al. Assessing tuberculosis control priorities in high-burden settings: A modelling approach. Lancet Glob Health. 2019;7:e585-95. https://doi.org/10.1016/S2214-109X(19)30037-3
7. World Health Organization. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: 2019. Fecha de consulta: 13 de agosto de 2019. Disponible en: http://apps.who.int/bookorders
8. Trebucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis. 2018;22:17-25. https://doi.org/10.5588/ijtld.17.0498
9. Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW. Risk factors of multidrugresistant tuberculosis: A global systematic review and meta-analysis. J Infect. 2018;77:469-78. https://doi.org/10.1016/j.jinf.2018.10.004
10. Ballestero JG, d´Auria de Lima MC, García JM, Gonzales RI, Sicsú AN, Mitano F, et al. Estratégias de controle e atenção à tuberculose multirresistente: uma revisão da literature. Rev Panam Salud Pública. 2019;43:e20. https://doi.org/10.26633/RPSP.2019.20
11. World Health Organization. Tuberculosis country profiles. 2017. Fecha de consulta: 10 de agosto de 2019. Disponible en: http://www.who.int/tb/country/data/profiles/en/
12. Ministerios de Salud y Protección Social, Organización Panamericana de la Salud. Plan estratégico “Hacia el fin de la tuberculosis”, Colombia, 2016-2025. Bogotá: 2016. Fecha de consulta: 20 de agosto de 2019. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/
BibliotecaDigital/RIDE/INEC/INTOR/Plan-estrategico-fin-tuberculosis-colombia-2016-2025.pdf